Print

Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of around 15 different brokers.

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB 9 Months 2017 Consensus (Average + Median)

In € million 9m 2016A 9m 2017e
(Average)
9m 2017e
(Median) 
Revenue 3,075 3,239 3,319
Immunology / Cimzia 933 1,016 1,013
Neurology 1,361 1,602 1,605
Vimpat 583 712 712
Keppra 541 594 596
Briviact 11 58 56
Neupro 219 235 236

 

UCB FY Consensus Product Sales Estimates (Average)

In € million 2017e 2018e 2019e  2020e  2021e  2022e
Cimzia 1,423 1,474 1,504 1,504 1,477 1,420
Vimpat 963 1,083 1,196 1,310 1,399 1,060
Neupro 328 349 367 379 345 290
Briviact 81 145 208 262 310 355
Keppra 719 686 653 615 573 542

 

UCB FY Consensus Earnings Estimates (Average)

In € million 2017e 2018e 2019e 
Revenue 4,400 4,571 4,701
Recurring EBIT 984 1,098 1,203
Recurring EBITDA 1,218 1,326 1,426
Net Profit  650 743 831
Core EPS (€) 3.90 4.38 4.83

 

UCB FY Consensus Product Sales Estimates (Median)

In € million 2017e 2018e 2019e  2020e  2021e  2022e
Cimzia 1,431 1,473 1,540 1,540 1,520 1,433
Vimpat 959 1,074 1,167 1,266 1,361 1,088
Neupro 327 346 365 385 350 288
Briviact 78 144 216 264 305 360
Keppra 727 692 645 605 583 543

 

UCB FY Consensus Earnings Estimates (Median)

In € million 2017e 2018e 2019e 
Revenue 4,397 4,576 4,675
Recurring EBIT 991 1,097 1,200
Recurring EBITDA 1,207 1,321 1,434
Net Profit  663 719 814
Core EPS (€) 4.02 4.43 4.93

Downloads:
UCB 9 Months 2017 Consensus (Excel)
UCB 9 Months 2017 Consensus (PDF
UCB FY 2017 Consensus (Excel)
UCB FY P&L Consensus ( PDF )
UCB FY Product Sales Consensus (PDF)  

Last updated:
9 months Consensus: October 16, 2017
FY Consensus: September 18, 2017



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.